Partnership Overview

Cognixion, known for its noninvasive brain-computer interface (BCI) technology, has partnered with Blackrock Neurotech, a leader in implantable BCIs. This collaboration will enable Blackrock to distribute Cognixion’s Axon-R wearable neural interface platform to research institutions through its established distribution network.

About Axon-R

• Axon-R is a noninvasive wearable device designed for precise measurement and modulation of brain activity.
• It utilizes visual stimuli, biofeedback, and neurofeedback for its operations.
• This device is intended solely for investigational use in neuroscience, education, and neurorehabilitation.
• It has not received FDA clearance for clinical or therapeutic applications.

Statements from Leadership

Andreas Forsland, CEO of Cognixion, stated, “This collaboration represents a strong alignment of complementary technologies that will significantly impact neurotechnology applications.” He emphasized that the combination of Blackrock’s implant technology with Cognixion’s AI and augmented reality platform will create new opportunities for researchers and clinicians.

Marcus Gerhardt, CEO of Blackrock Neurotech, added, “By expanding access to research-grade tools like Axon-R, we aim to support the early exploration of neural interfaces while maintaining our clinical focus on high-fidelity implantable technologies that restore speech, movement, and sensation.”

Industry Context

In March, Forsland discussed the potential of augmented reality, AI, and BCI technologies to assist patients with traumatic brain injuries, strokes, and ALS in communicating through eye movements.

Looking ahead, in 2024, Noldus Information Technology plans to collaborate with Blackrock Neurotech to integrate its EthoVision XT behavioral tracking software with Blackrock’s electrophysiology systems. This integration aims to synchronize behavioral tracking data with EEG recordings for enhanced research accuracy.

Other Developments in the BCI Sector

• Synchron has announced it will be the first BCI company to achieve native integration with Apple’s BCI Human Interface Device (BCI HID) profile, allowing users to control devices like iPhones and iPads using their thoughts.
• Neuralink recently implanted its BCI into a patient with ALS, enabling him to communicate using a telepathic interface.
• Neuralink has also filed for trademarks related to its BCI technologies, including terms like “Telepathy” and “Blindsight.”

As the BCI landscape evolves, partnerships like that of Cognixion and Blackrock Neurotech are paving the way for innovative research and applications in neurotechnology.